DIAXONHIT announced consolidated earnings results for the year ended December 31, 2015. Sales of in vitro diagnostic products increased by 4% and a consolidated income was EUR 29.5 million compared to EUR 30.6 million as of December 31, 2014, following the end of the collaboration with Allergan. Total annual sales of in vitro diagnostic products reached EUR 28.9 million, an increase of 4% compared to sales of EUR 27.9 million recorded for the year 2014.

This growth offsets to a large extent the end of the Allergan partnership and the corresponding revenues.